X4 Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:X4 Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013412
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
X4 Pharmaceuticals Inc (X4 Pharma) is a clinical stage biotechnology company that develops novel therapeutics to treat cancer and rare diseases. The company’s lead drug candidate, X4P-001-LD, is in Phase 2/3 trial used for the treatment for patients with WHIM and other immunodeficiencies. It also develops X4P-001, a CXCR4 inhibitor used for the treatment of melanoma, refractory clear cell renal cell carcinoma (ccRCC), and other solid tumor indications. X4 Pharma’s pre-clinical products include X4P-002, designed for the treatment of brain cancers, including glioblastoma multiforme. X4 Pharma is headquartered in Cambridge, Massachusetts, the US.

X4 Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
X4 Pharma Raises USD25.8 Million in Venture Financing 10
X4 Pharma Raises USD37.5 Million in Series A Financing Round 11
X4 Pharma Raises USD0.7 Million in Seed Financing Round 12
Partnerships 13
X4 Pharma Enters into Research Agreement with Yale University 13
Equity Offering 14
X4 Pharma Spin Off from Sanofi 14
X4 Pharmaceuticals Inc – Key Competitors 15
X4 Pharmaceuticals Inc – Key Employees 16
X4 Pharmaceuticals Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Jan 23, 2017: X4 Pharmaceuticals Appoints Dr. Sudha Parasuraman as Chief Medical Officer 18
Oct 04, 2016: X4 Pharmaceuticals Appoints Nancy Lurker as Chair of Board of Directors 19
Jun 13, 2016: X4 Pharmaceuticals Appoints John K. Celebi as Chief Operating Officer 20
Product News 21
05/25/2017: X4 Pharmaceuticals Announces Initiation of the Phase 2 Expansion of its Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma 21
01/30/2017: X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-LD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease 22
01/26/2017: X4 Pharmaceuticals Announces Initiation of Clinical Study of X4P-001 in Combination with Opdivo for Patients with Advanced Clear Cell Renal Cell 23
Clinical Trials 24
Nov 30, 2016: X4 Pharmaceuticals announces new data for lead candidate X4P-001 in renal cell carcinoma at EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium 24
Sep 27, 2016: X4 Pharmaceuticals Announces Initiation of Phase 1b Study of X4P-001 in Patients with Resectable Stage III and Stage IV Melanoma 25
Apr 19, 2016: X4 Pharmaceuticals Announces Data Presentation for Lead Candidate X4P-001 at AACR Annual Meeting 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
X4 Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
X4 Pharma Raises USD25.8 Million in Venture Financing 10
X4 Pharma Raises USD37.5 Million in Series A Financing Round 11
X4 Pharma Raises USD0.7 Million in Seed Financing Round 12
X4 Pharma Enters into Research Agreement with Yale University 13
X4 Pharma Spin Off from Sanofi 14
X4 Pharmaceuticals Inc, Key Competitors 15
X4 Pharmaceuticals Inc, Key Employees 16

★海外企業調査レポート[X4 Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nightstar Therapeutics PLC (NITE):製薬・医療:M&Aディール及び事業提携情報
    Summary Nightstar Therapeutics PLC (Nightstar Therapeutics), formerly Nightstar Therapeutics Ltd, is a clinical-stage gene therapy company. The company focus on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. Its lead product cand …
  • The Real Good Food Company plc:戦略・SWOT・企業財務分析
    The Real Good Food Company plc - Strategy, SWOT and Corporate Finance Report Summary The Real Good Food Company plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • CryoLife Inc (CRY):医療機器:M&Aディール及び事業提携情報
    Summary CryoLife Inc (CryoLife) is a provider of biosurgical devices and implantable living tissues for cardiac and vascular surgical procedures. The company’s portfolio enlists preserved human cardiac allografts, vascular allografts, surgical adhesives and sealants, heart valves, carbon dioxide dif …
  • ALTANA AG:企業のM&A・事業提携・投資動向
    ALTANA AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ALTANA AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Jyoti Structures Ltd (JYOTISTRUC):電力:M&Aディール及び事業提携情報
    Summary Jyoti Structures Ltd (JSL) is a turnkey engineering, procurement, and construction (EPC) services provider that designs, tests, manufactures, sources, constructs, and supplies transmission lines, substations, and microwave towers. It designs HVDC and river crossing transmission towers, subst …
  • AGA Rangemaster Group Ltd:企業の戦略的SWOT分析
    AGA Rangemaster Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Ryerson Holding Corp:企業の戦略・SWOT・財務情報
    Ryerson Holding Corp - Strategy, SWOT and Corporate Finance Report Summary Ryerson Holding Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Vietnam Prosperity Joint-Stock Commercial Bank (VPB):企業の財務・戦略的SWOT分析
    Vietnam Prosperity Joint-Stock Commercial Bank (VPB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …
  • Myer Holdings Ltd:企業の戦略・SWOT・財務分析
    Myer Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Myer Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Andrade Gutierrez SA:企業の戦略的SWOT分析
    Andrade Gutierrez SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Cytodyn Inc (CYDY):製薬・医療:M&Aディール及び事業提携情報
    Summary Cytodyn Inc (Cytodyn) is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies t for the treatment of Human Immunodeficiency Virus (HIV) infections. The company's products pipeline include PRO 140, Cytofe …
  • China Resources Gas Group Ltd (1193):石油・ガス:M&Aディール及び事業提携情報
    Summary China Resources Gas Group Ltd (CR Gas), a subsidiary of China Resources (Holdings) Co Ltd, is a gas company that offers distribution of natural gas and petroleum gas. The company provides downstream city gas distribution business including piped natural gas distribution and natural gas filli …
  • Goldman Sachs Group Inc:戦略・SWOT・企業財務分析
    Goldman Sachs Group Inc - Strategy, SWOT and Corporate Finance Report Summary Goldman Sachs Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Charkit Chemical Company LLC:企業の戦略・SWOT・財務情報
    Charkit Chemical Company LLC - Strategy, SWOT and Corporate Finance Report Summary Charkit Chemical Company LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Dover Corp (DOV):企業の財務・戦略的SWOT分析
    Dover Corp (DOV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Technicolor SA:企業の戦略・SWOT・財務情報
    Technicolor SA - Strategy, SWOT and Corporate Finance Report Summary Technicolor SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Calfrac Well Services Ltd. (CFW):企業の財務・戦略的SWOT分析
    Calfrac Well Services Ltd. (CFW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Minnesota Municipal Power Agency:企業の戦略的SWOT分析
    Minnesota Municipal Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Novo Nordisk AS (NOVO B):企業の財務・戦略的SWOT分析
    Novo Nordisk AS (NOVO B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Exicure Inc (XCUR):製薬・医療:M&Aディール及び事業提携情報
    Summary Exicure Inc (Exicure), formerly AuraSense Therapeutics LLC is a biotechnology company that discovers, develops, and commercializes immunomodulatory and gene silencing drugs based on 3-dimensional spherical nucleic acid constructs. The company’s technology portfolio includes SNA gene regulati …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆